• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Kimball Electronics, Inc. Announces Appointment of Additional Director

    9/15/22 4:05:00 PM ET
    $BHC
    $KE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Electrical Products
    Technology
    Get the next $BHC alert in real time by email

    Kimball Electronics, Inc. (NASDAQ:KE), announces the expansion of its Board of Directors and appointment of a new director at its regularly scheduled Board Meeting on September 13, 2022.

    Tom Vadaketh was selected to the Company's Board of Directors (the "Board"), effective as of the September meeting. Mr. Vadaketh will serve on the Audit Committee and will stand for election to a full term at the 2022 Annual Meeting of Share Owners in November.

    Mr. Vadaketh serves as Chief Financial Officer of Bausch Health (NYSE:BHC) (TSX:BHC), which develops, manufactures, and markets pharmaceuticals, over-the-counter products, and medical devices globally, primarily in the therapeutic areas of eye-health, gastroenterology, and dermatology.

    Prior to joining Bausch Health in January 2022, Mr. Vadaketh served as Executive Vice President and Chief Financial Officer of eResearch Technology, Inc. from September 2018 to December 2021, where he was responsible for leading the Finance function including controllership, treasury, taxation, and financial planning.

    Prior to that, he was Executive Vice President and Chief Financial Officer of Cambrex Corporation. In addition, Mr. Vadaketh spent over 20 years at Procter & Gamble and Tyco International, where he held several roles of increasing responsibility at both companies.

    Mr. Vadaketh received a degree from the Institute of Chartered Accountants in England and Wales (ACA) and an M.B.A. from Manchester Business School. He is a Certified Public Accountant.

    "Speaking on behalf of our Board, it is an honor to have Tom join us with his well-rounded financial expertise, vast experience with major multinational organizations, and demonstrated leadership in a variety of global businesses driving both organic growth and strategic acquisitions," said Don Charron, Chairman of the Board and Chief Executive Officer. "Tom further enhances our Board's distinct and valuable skill sets as we continue to build lasting relationships and global success with our stakeholders. We expect to learn a lot from Tom so that we become an even better company while creating quality for life."

    About Kimball Electronics, Inc.

    Kimball Electronics is a multifaceted manufacturing solutions provider of electronics and diversified contract manufacturing services to customers around the world. From our operations in the United States, China, India, Japan, Mexico, Poland, Romania, Thailand, and Vietnam, our teams are proud to provide manufacturing services for a variety of industries. Recognized for a reputation of excellence, we are committed to a high-performance culture that values personal and organizational commitment to quality, reliability, value, speed, and ethical behavior. Kimball Electronics, Inc. (NASDAQ:KE) is headquartered in Jasper, Indiana.

    To learn more about Kimball Electronics, visit: www.kimballelectronics.com.

    Lasting relationships. Global success.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20220915005963/en/

    Get the next $BHC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BHC
    $KE

    CompanyDatePrice TargetRatingAnalyst
    Kimball Electronics Inc.
    $KE
    7/2/2026Sector Weight
    KeyBanc Capital Markets
    Bausch Health Companies Inc.
    $BHC
    12/9/2025$8.00Equal Weight
    Barclays
    Kimball Electronics Inc.
    $KE
    8/15/2024Buy → Neutral
    Sidoti
    Bausch Health Companies Inc.
    $BHC
    8/2/2024$9.00 → $3.00Neutral → Underweight
    Piper Sandler
    Bausch Health Companies Inc.
    $BHC
    7/10/2024$8.00Mkt Perform
    Raymond James
    Kimball Electronics Inc.
    $KE
    10/9/2023$39.00Buy
    B. Riley Securities
    Bausch Health Companies Inc.
    $BHC
    9/20/2023$9.00 → $16.00Hold → Buy
    Jefferies
    Bausch Health Companies Inc.
    $BHC
    6/16/2023Outperform → Market Perform
    TD Cowen
    More analyst ratings

    $BHC
    $KE
    SEC Filings

    View All

    Bausch Health Companies Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Bausch Health Companies Inc. (0000885590) (Filer)

    7/1/26 4:23:22 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kimball Electronics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Kimball Electronics, Inc. (0001606757) (Filer)

    7/1/26 7:20:21 AM ET
    $KE
    Electrical Products
    Technology

    SEC Form 11-K filed by Kimball Electronics Inc.

    11-K - Kimball Electronics, Inc. (0001606757) (Filer)

    6/23/26 3:03:47 PM ET
    $KE
    Electrical Products
    Technology

    $BHC
    $KE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Kimball Electronics Launches Rebrand to Kimball Solutions, Marking First Phase Completion in Jasper and Indianapolis

    Kimball Electronics, Inc. (NASDAQ:KE) today announced a significant milestone in its evolution, with the successful completion of the first phase of its rebranding to Kimball Solutions at its Jasper and Indianapolis, Indiana facilities, effective July 1, 2026. This milestone reflects the Company’s continued transformation from a traditional electronics manufacturing services (EMS) provider into a global, diversified manufacturing and engineering solutions partner. A Name That Reflects a Broader Vision The transition to Kimball Solutions underscores the Company’s expanded capabilities across the full product lifecycle from design engineering and supply chain management to advanced manu

    7/15/26 4:05:00 PM ET
    $KE
    Electrical Products
    Technology

    Bausch Health to Announce Second Quarter 2026 Results on July 29, 2026

    LAVAL, QC, July 7, 2026 /CNW/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release second quarter 2026 financial results after market close on Wednesday, July 29, 2026. Bausch Health will host a live conference call and webcast at 5:00 p.m. U.S. EDT to discuss results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch Health website prior to the start of the call.Conference Call DetailsDate:                          Wednesday, July 29, 2026Time:                          5:00 p.m. U.S. EDTWebcast:                    http://ir.bauschhealth.com/events-and-presentationsA replay of the conference call will be available o

    7/7/26 7:00:00 AM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Québec is the first province to list (Pr)OKEDI(MC) (extended-release injectable suspension of risperidone) on the public drug reimbursement formulary for the treatment of schizophrenia

    LAVAL, QC, July 6, 2026 /CNW/ -- Bausch Health, Canada Inc., a subsidiary of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), announces the listing of PrOKEDI®  (extended-release injectable suspension of risperidone) 75 mg and 100 mg strengths to the drug formulary of the Régie de l'assurance maladie du Québec (RAMQ) effective June 25th, 2026, for the treatment of schizophrenia in adults.PrOKEDI® is a prolonged-release injectable suspension of risperidone indicated for the treatment of schizophrenia in adults. According to the Canadian product monograph, PrOKEDI® achieves clinically relevant concentrations of the active ingredient within the first few hours after injection, without the need

    7/6/26 7:00:00 AM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BHC
    $KE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President, US Pharma Lenar Aimee J. covered exercise/tax liability with 5,260 shares, decreasing direct ownership by 1% to 371,680 units (SEC Form 4) (for withholding tax)

    4 - Bausch Health Companies Inc. (0000885590) (Issuer)

    7/20/26 4:49:07 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President, US Pharma Lenar Aimee J. covered exercise/tax liability with 23,395 shares, decreasing direct ownership by 6% to 376,940 units (SEC Form 4) (tax liability)

    4 - Bausch Health Companies Inc. (0000885590) (Issuer)

    7/17/26 4:23:13 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVP, Controller & CAO Lee Steven Hyosig covered exercise/tax liability with 3,125 shares, decreasing direct ownership by 4% to 70,114 units (SEC Form 4) (tax withholding)

    4 - Bausch Health Companies Inc. (0000885590) (Issuer)

    7/15/26 5:20:09 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BHC
    $KE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    KeyBanc Capital Markets initiated coverage on Kimball Electronics

    KeyBanc Capital Markets initiated coverage of Kimball Electronics with a rating of Sector Weight

    7/2/26 8:19:15 AM ET
    $KE
    Electrical Products
    Technology

    Barclays initiated coverage on Bausch Health with a new price target

    Barclays initiated coverage of Bausch Health with a rating of Equal Weight and set a new price target of $8.00

    12/9/25 8:43:03 AM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kimball Electronics downgraded by Sidoti

    Sidoti downgraded Kimball Electronics from Buy to Neutral

    8/15/24 7:57:54 AM ET
    $KE
    Electrical Products
    Technology

    $BHC
    $KE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Paulson & Co. Inc. bought $15,625,000 worth of shares (2,500,000 units at $6.25) (SEC Form 4)

    4 - Bausch Health Companies Inc. (0000885590) (Issuer)

    11/28/25 5:38:39 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Paulson John bought $312,490,062 worth of shares (34,721,118 units at $9.00) (SEC Form 4)

    4 - Bausch Health Companies Inc. (0000885590) (Issuer)

    8/14/25 9:35:28 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Paulson John bought $21,267,731 worth of shares (3,243,049 units at $6.56) (SEC Form 4)

    4 - Bausch Health Companies Inc. (0000885590) (Issuer)

    8/13/25 6:51:24 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BHC
    $KE
    Financials

    Live finance-specific insights

    View All

    Bausch Health to Announce Second Quarter 2026 Results on July 29, 2026

    LAVAL, QC, July 7, 2026 /CNW/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release second quarter 2026 financial results after market close on Wednesday, July 29, 2026. Bausch Health will host a live conference call and webcast at 5:00 p.m. U.S. EDT to discuss results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch Health website prior to the start of the call.Conference Call DetailsDate:                          Wednesday, July 29, 2026Time:                          5:00 p.m. U.S. EDTWebcast:                    http://ir.bauschhealth.com/events-and-presentationsA replay of the conference call will be available o

    7/7/26 7:00:00 AM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kimball Electronics Acquires European-Based Medical CDMO, Helvoet Polymer Technologies B.V.

    Helvoet is an advanced medical CDMO specializing in highly automated micro-molding and precision injection molding for microfluidics, diagnostics, and drug delivery applications Acquisition establishes a global medical CMO platform by expanding the Kimball manufacturing footprint in Europe while adding production facilities in India Transaction is expected to be accretive to fiscal 2027 adjusted earnings, increasing sales in the Kimball medical vertical in the low double-digit range Helvoet customer base includes blue-chip medical companies complementary to the Kimball portfolio, creating opportunities for expanded program wins and possible vertical integration Kimball manu

    7/1/26 2:00:00 AM ET
    $KE
    Electrical Products
    Technology

    Kimball Electronics Reports Q3 Results With Double-Digit Sequential Medical Sales Growth; Company Affirms Guidance for Fiscal 2026 With Adjusted Operating Margin Expected at High End of Range

    Third Quarter 2026 Highlights Revenue of $352.9 million, a sequential increase of 3.4% compared to Q2 Sales in the medical vertical increased 10.2% versus the prior quarter Operating income of $11.8 million, or 3.3% of net sales, adjusted operating margin of 4.2% Cash from operations of $14.9 million, the ninth consecutive quarter of positive operating cash generation Debt of $163.0 million and borrowing capacity of $276.0 million Cash Conversion Days of 90, an improvement compared to both the prior quarter and Q3 of fiscal 2025 Invested $4.0 million to repurchase 165,000 shares of common stock Company affirms guidance for fiscal 2026 with adjusted operating margin e

    5/5/26 4:05:00 PM ET
    $KE
    Electrical Products
    Technology

    $BHC
    $KE
    Leadership Updates

    Live Leadership Updates

    View All

    Bausch Health Announces 2026 Annual Meeting of Shareholder Results

    LAVAL, QC, May 19, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that shareholders elected all 10 director nominees at its 2026 Annual Meeting of Shareholders ("Annual Meeting") held on May 19, 2026, including Eiry W. Roberts, M.D., who was elected as a new director. Dr. Roberts brings extensive pharmaceutical leadership experience, including expertise in clinical development, medical strategy and business development, and previously served as Chief Medical Officer of Neurocrine Biosciences, Inc. Dr. Roberts will serve as chair of the Science and Technology Committee.Detailed results of the vote follow:NameForWithheldBroker Non-VotesThomas J. Appio196,

    5/19/26 4:15:00 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kimball Electronics Intensifies Focus on Strategic Development With Appointment of a New Member to Its Leadership Team; Company to Participate at the Piper Sandler 37th Annual Healthcare Conference

      Kimball Electronics, Inc. (NASDAQ:KE) today announced the Company is intensifying its focus on strategic development with the appointment of a new member to its leadership team. Andrew D. Regrut, Treasurer and Investor Relations Officer, will now also lead the strategic development efforts of the Company. Commenting on Mr. Regrut's expanded role, Jana T. Croom, Chief Financial Officer, stated, "I'm thrilled to be announcing Andy's promotion and addition to our leadership team. He has been instrumental in our recent efforts to optimize debt levels through improved working capital management and global cash movement. We look for his energy and intensity to elevate our focus on strategic d

    12/2/25 8:30:00 AM ET
    $KE
    Electrical Products
    Technology

    Bausch Health Appoints New Chief Medical Officer and Head of R&D

    LAVAL, QC / ACCESSWIRE / December 2, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is pleased to announce the appointment of Jonathan Sadeh M.D., M.Sc as Executive Vice President, Chief Medical Officer and Head of R&D. This strategic addition to our leadership team underscores our commitment to innovation, excellence, and enriching lives.Jonathan brings a wealth of experience and a proven track record of success both as a physician-scientist and a leader in the pharmaceutical industry. With over 20 years of expertise in clinical research and drug development, he has consistently demonstrated the ability to drive growth and foster innovation. Most recently, at Bristol-Meyers Squibb,

    12/2/24 8:00:00 AM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BHC
    $KE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Kimball Electronics Inc.

    SC 13G/A - Kimball Electronics, Inc. (0001606757) (Subject)

    11/12/24 3:47:56 PM ET
    $KE
    Electrical Products
    Technology

    Amendment: SEC Form SC 13G/A filed by Kimball Electronics Inc.

    SC 13G/A - Kimball Electronics, Inc. (0001606757) (Subject)

    11/4/24 11:46:47 AM ET
    $KE
    Electrical Products
    Technology

    SEC Form SC 13G filed by Bausch Health Companies Inc.

    SC 13G - Bausch Health Companies Inc. (0000885590) (Subject)

    8/30/24 6:12:52 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care